CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: MPV17L (ImmuneEditome ID:255027)

1. Gene summary of enriched editing regions for MPV17L

check button Gene summary
Gene informationGene symbol

MPV17L

Gene ID

255027

GeneSynonymsM-LPH|MLPH1|MLPH2|MPV17L1
GeneCytomap

16p13.11

GeneTypeprotein-coding
GeneDescriptionmpv17-like protein|M-LP homolog|MPV17 mitochondrial membrane protein-like|Mpv17-like protein type 1|Mpv17-like protein type 2
GeneModificationdate20230518
UniprotIDH3BT45;Q2QL34;H3BMD7
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr16:15402769-15403586:+ENST00000287594.7ENSG00000156968.8MPV17LintronicAluSc8,AluSx,AluJb,(T)nchr16:15402769-15403586:+.alignment
chr16:15402769-15403586:+ENST00000396385.3ENSG00000156968.8MPV17LintronicAluSc8,AluSx,AluJb,(T)nchr16:15402769-15403586:+.alignment
chr16:15402769-15403586:+ENST00000564148.1ENSG00000156968.8MPV17LintronicAluSc8,AluSx,AluJb,(T)nchr16:15402769-15403586:+.alignment
chr16:15408654-15412903:+ENST00000287594.7ENSG00000156968.8MPV17LUTR3AluY,LTR7B,AluSz,(ATGA)n,AluYh3,AluSz6,AluJo,AluSx,FLAM_Cchr16:15408654-15412903:+.alignment


Top

2. Tumor-specific enriched editing regions for MPV17L


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr16:15408654-15412903:+BRCAEER1.4383e-02image
ENSG00000156968.8,MPV17LBRCAEAG1.3847e-02image
chr16:15408654-15412903:+KICHEER4.1377e-02image
ENSG00000156968.8,MPV17LKICHEAG4.1377e-02image
chr16:15408654-15412903:+KIRCEER1.2742e-05image
ENSG00000156968.8,MPV17LKIRCEAG1.2752e-05image
chr16:15408654-15412903:+LIHCEER7.0064e-03image
ENSG00000156968.8,MPV17LLIHCEAG7.0024e-03image
chr16:15408654-15412903:+THCAEER2.2910e-05image
ENSG00000156968.8,MPV17LTHCAEAG2.2910e-05image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000156968.8,MPV17LACCPathEAG2.6795e-024.9225e-03-0.3614image
chr16:15408654-15412903:+ACCPathEER2.6795e-024.9225e-03-0.3614image
ENSG00000156968.8,MPV17LKIRPCliEAG4.9908e-022.0341e-020.1773image
chr16:15408654-15412903:+KIRPCliEER4.9945e-022.0363e-020.1773image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr16:15408654-15412903:+ACCEER4.2474e-041.3937e-023.4970e-06image
ENSG00000156968.8,MPV17LACCEAG4.2474e-041.3937e-023.4970e-06image

Top

3. Enriched editing regions and immune related genes for MPV17L


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr16:15408654-15412903:+KIRCEERENSG00000134597,RBMX20.32061.2421e-069.2494e-140.4070imageNNNAMonocytesGSVA_HALLMARK_BILE_ACID_METABOLISM
chr16:15408654-15412903:+PCPGEERENSG00000175104,TRAF6-0.55023.5172e-091.0789e-10-0.4904imageNNTRAF6T_cells_follicular_helperGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:15408654-15412903:+PCPGEERENSG00000110768,GTF2H1-0.53221.8913e-085.2642e-10-0.4741imageNNNAMast_cells_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:15408654-15412903:+PCPGEERENSG00000129083,COPB1-0.51548.4660e-085.6480e-10-0.4734imageNNNADendritic_cells_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr16:15408654-15412903:+PCPGEERENSG00000213713,PIGCP1-0.51379.7507e-087.2344e-10-0.4708imageNNNAGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:15408654-15412903:+PCPGEERENSG00000176148,TCP11L1-0.50791.5261e-077.7479e-09-0.4444imageNNNADendritic_cells_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:15408654-15412903:+PCPGEERENSG00000132405,TBC1D14-0.50621.7053e-072.4219e-10-0.4822imageNNNANeutrophilsGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:15408654-15412903:+PCPGEERENSG00000265282,RP11-269G24.4-0.49882.8396e-073.3219e-08-0.4271imageNNNADendritic_cells_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:15408654-15412903:+PCPGEERENSG00000166689,PLEKHA7-0.49493.9833e-071.6081e-08-0.4358imageNNPLEKHA7T_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:15408654-15412903:+PCPGEERENSG00000243232,PCDHAC2-0.49324.3902e-071.0617e-07-0.4125imageNNPCDHAC2Dendritic_cells_restingGSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

4. Enriched editing regions and immune related splicing for MPV17L


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000156968.8,MPV17L
KIRCEAGIRENSG00000152527.9chr243743833:43743989:43745865:437459630.21701.1956e-034.1938e-110.4181imageNADAR;BUD13;CSTF2T;EIF4A3;ELAVL1;FAM120A;FBL;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;PCBP2;PRPF8;PTBP1;RBFOX2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1NAMonocytesGSVA_HALLMARK_HEME_METABOLISM
chr16:15408654-15412903:+
KIRCEERIRENSG00000152527.9chr243743833:43743989:43745865:437459630.21701.1251e-034.1992e-110.4181imageNNNAMonocytesGSVA_HALLMARK_HEME_METABOLISM
chr16:15408654-15412903:+
PCPGEERA3ENSG00000126214.16chr14103692358:103692425:103700654:103700727:103693552:1037007270.43179.7979e-052.6003e-070.4032imageNNNAB_cells_memoryGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000156968.8,MPV17L
PCPGEAGMEXENSG00000159063.8chr1178104355:78104453:78106806:78106912:78127357:78127436:78139493:781395920.45621.5019e-055.9190e-080.4199imageNADAR;AUH;BCCIP;BUD13;CSTF2T;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;PCBP2;PRPF8;PTBP1;RBFOX2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;UPF1NAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000156968.8,MPV17L
PCPGEAGMEXENSG00000013561.13chr5141973582:141973742:141974803:141974955:141983381:141983552:141984802:141984933-0.46151.5038e-052.6014e-07-0.4020imageNADAR;BUD13;CSTF2T;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;PCBP2;PRPF8;PTBP1;RBFOX2;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1NANeutrophilsGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000156968.8,MPV17L
PCPGEAGMEXENSG00000159063.8chr1178104355:78104453:78106806:78106946:78127357:78127436:78139493:781395920.45621.5100e-055.8954e-080.4200imageNADAR;AUH;BCCIP;BUD13;CSTF2T;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;PCBP2;PRPF8;PTBP1;RBFOX2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;UPF1NAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000156968.8,MPV17L
PCPGEAGIRENSG00000242265.1chr794664734:94665075:94668733:94669180-0.40831.4771e-045.9636e-07-0.4032imageNADAR;AUH;BCCIP;BUD13;CSTF2T;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LARP7;LIN28B;PCBP2;PRPF8;PTBP1;PUM2;RBFOX2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;UPF1PEG10NeutrophilsGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:15408654-15412903:+
PCPGEERMEXENSG00000096384.15chr644247086:44247195:44248629:44248776:44252162:44252267:44253044:44253378-0.45882.3121e-057.1936e-08-0.4175imageNNHSP90AB1NeutrophilsGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000156968.8,MPV17L
PCPGEAGIRENSG00000005436.9chr275662705:75664783:75665928:75665941-0.45462.5454e-052.8058e-08-0.4291imageNADAR;AUH;BCCIP;BUD13;CSTF2T;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LIN28B;PCBP2;PRPF8;PTBP1;PUM2;RBFOX2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1NANeutrophilsGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000156968.8,MPV17L
PCPGEAGIRENSG00000160710.11chr1154585216:154585344:154585752:1545858650.38127.6056e-043.5840e-070.4077imageNADAR;AUH;BCCIP;BUD13;CSTF2T;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LARP7;LIN28B;PCBP2;PRPF8;PTBP1;PUM2;RBFOX2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;UPF1ADARGSVA_HALLMARK_PROTEIN_SECRETION

More results



Top

5. Enriched editing regions and immune infiltration for MPV17L


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr16:15408654-15412903:+ACCEERDendritic_cells_activated2.7817e-02-0.2818image
ENSG00000156968.8,MPV17LACCEAGDendritic_cells_activated2.7817e-02-0.2818image
chr16:15408654-15412903:+BRCAEERMast_cells_resting6.6919e-08-0.1781image
ENSG00000156968.8,MPV17LBRCAEAGMast_cells_resting1.1629e-07-0.1748image
chr16:15408654-15412903:+CESCEERT_cells_CD4_memory_resting2.0817e-02-0.2309image
ENSG00000156968.8,MPV17LCESCEAGT_cells_CD4_memory_resting2.0807e-02-0.2309image
chr16:15408654-15412903:+CHOLEERT_cells_regulatory_(Tregs)1.6592e-02-0.4743image
ENSG00000156968.8,MPV17LCHOLEAGT_cells_regulatory_(Tregs)1.6592e-02-0.4743image
chr16:15408654-15412903:+COADEERDendritic_cells_activated9.9514e-040.2725image
ENSG00000156968.8,MPV17LCOADEAGDendritic_cells_activated8.5087e-040.2759image
chr16:15408654-15412903:+ESCAEERMacrophages_M22.2072e-020.2347image
ENSG00000156968.8,MPV17LESCAEAGMacrophages_M22.2072e-020.2347image
chr16:15408654-15412903:+GBMEERMacrophages_M11.0622e-020.2047image
ENSG00000156968.8,MPV17LGBMEAGMacrophages_M11.0622e-020.2047image
chr16:15408654-15412903:+HNSCEERB_cells_naive5.9204e-03-0.3258image
ENSG00000156968.8,MPV17LHNSCEAGB_cells_naive5.9204e-03-0.3258image
chr16:15408654-15412903:+KIRCEERT_cells_regulatory_(Tregs)1.4971e-040.2141image
ENSG00000156968.8,MPV17LKIRCEAGT_cells_regulatory_(Tregs)1.4920e-040.2141image
chr16:15408654-15412903:+KIRPEERNK_cells_resting2.7497e-030.1917image
ENSG00000156968.8,MPV17LKIRPEAGNK_cells_resting2.7486e-030.1917image
chr16:15408654-15412903:+LGGEERB_cells_memory3.1430e-020.1028image
ENSG00000156968.8,MPV17LLGGEAGB_cells_memory3.1430e-020.1028image
chr16:15408654-15412903:+LIHCEERT_cells_gamma_delta6.3237e-040.1818image
ENSG00000156968.8,MPV17LLIHCEAGT_cells_gamma_delta6.3201e-040.1818image
chr16:15408654-15412903:+LUADEERT_cells_CD83.0250e-020.1752image
ENSG00000156968.8,MPV17LLUADEAGT_cells_CD83.0250e-020.1752image
chr16:15408654-15412903:+LUSCEERB_cells_naive1.6564e-02-0.1593image
ENSG00000156968.8,MPV17LLUSCEAGB_cells_naive1.6564e-02-0.1593image
chr16:15408654-15412903:+OVEERT_cells_gamma_delta3.1819e-020.1638image
ENSG00000156968.8,MPV17LOVEAGT_cells_gamma_delta3.1808e-020.1638image
chr16:15408654-15412903:+PAADEERB_cells_naive1.0261e-02-0.2495image
ENSG00000156968.8,MPV17LPAADEAGB_cells_naive1.0261e-02-0.2495image
chr16:15408654-15412903:+PCPGEERMacrophages_M01.7929e-050.3382image
ENSG00000156968.8,MPV17LPCPGEAGMacrophages_M01.7929e-050.3382image
chr16:15408654-15412903:+PRADEERT_cells_CD4_memory_resting2.2371e-02-0.1178image
ENSG00000156968.8,MPV17LPRADEAGT_cells_CD4_memory_resting2.2371e-02-0.1178image
chr16:15408654-15412903:+READEERT_cells_CD4_naive7.2739e-040.4580image
ENSG00000156968.8,MPV17LREADEAGT_cells_CD4_naive7.2739e-040.4580image
chr16:15408654-15412903:+SARCEERMast_cells_resting3.5165e-02-0.1776image
ENSG00000156968.8,MPV17LSARCEAGMast_cells_resting3.5165e-02-0.1776image
chr16:15408654-15412903:+SKCMEERNeutrophils3.6978e-020.2058image
ENSG00000156968.8,MPV17LSKCMEAGNeutrophils3.6978e-020.2058image
chr16:15408654-15412903:+STADEERT_cells_CD4_memory_resting3.0362e-03-0.1922image
ENSG00000156968.8,MPV17LSTADEAGT_cells_CD4_memory_resting3.1657e-03-0.1913image
chr16:15408654-15412903:+TGCTEERMast_cells_resting7.9081e-050.3404image
ENSG00000156968.8,MPV17LTGCTEAGMast_cells_resting7.9081e-050.3404image
chr16:15408654-15412903:+THCAEERT_cells_follicular_helper4.9237e-030.1281image
ENSG00000156968.8,MPV17LTHCAEAGT_cells_follicular_helper4.9237e-030.1281image
chr16:15408654-15412903:+THYMEERDendritic_cells_resting6.7124e-030.4323image
ENSG00000156968.8,MPV17LTHYMEAGDendritic_cells_resting6.7124e-030.4323image
chr16:15408654-15412903:+UCECEERMacrophages_M13.0481e-030.4319image
ENSG00000156968.8,MPV17LUCECEAGMacrophages_M13.0481e-030.4319image
chr16:15408654-15412903:+UVMEERT_cells_CD4_memory_activated2.0047e-020.3157image
ENSG00000156968.8,MPV17LUVMEAGT_cells_CD4_memory_activated2.0047e-020.3157image


Top

6. Enriched editing regions and immune gene sets for MPV17L


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr16:15408654-15412903:+THCAEER2.5076e-02image2.0902e-020.1054image
ENSG00000156968.8,MPV17LTHCAEAG2.5076e-02image2.0902e-020.1054image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr16:15408654-15412903:+BRCAEER6.0399e-110.21505.5417e-040.11441.4770e-030.10543.5270e-030.0968image
ENSG00000156968.8,MPV17LBRCAEAG7.5777e-110.21396.0428e-040.11371.6128e-030.10464.1279e-030.0952image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr16:15408654-15412903:+ACCGSVA_HALLMARK_MYC_TARGETS_V2EER3.7796e-03-0.3654image
ENSG00000156968.8,MPV17LACCGSVA_HALLMARK_MYC_TARGETS_V2EAG3.7796e-03-0.3654image
chr16:15408654-15412903:+BLCAGSVA_HALLMARK_NOTCH_SIGNALINGEER3.8811e-020.2060image
ENSG00000156968.8,MPV17LBLCAGSVA_HALLMARK_NOTCH_SIGNALINGEAG3.8811e-020.2060image
ENSG00000156968.8,MPV17LBRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG8.5416e-130.2345image
chr16:15408654-15412903:+BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER5.4334e-130.2365image
chr16:15408654-15412903:+CESCGSVA_HALLMARK_P53_PATHWAYEER5.1394e-040.3412image
ENSG00000156968.8,MPV17LCESCGSVA_HALLMARK_P53_PATHWAYEAG5.1347e-040.3412image
ENSG00000156968.8,MPV17LCHOLGSVA_HALLMARK_APICAL_SURFACEEAG8.1050e-030.5172image
chr16:15408654-15412903:+CHOLGSVA_HALLMARK_APICAL_SURFACEEER8.1050e-030.5172image
chr16:15408654-15412903:+COADGSVA_HALLMARK_PEROXISOMEEER3.6464e-04-0.2940image
ENSG00000156968.8,MPV17LCOADGSVA_HALLMARK_PEROXISOMEEAG3.1646e-04-0.2970image
ENSG00000156968.8,MPV17LESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG1.4855e-030.3216image
chr16:15408654-15412903:+ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER1.4855e-030.3216image
ENSG00000156968.8,MPV17LGBMGSVA_HALLMARK_SPERMATOGENESISEAG7.6430e-03-0.2135image
chr16:15408654-15412903:+GBMGSVA_HALLMARK_SPERMATOGENESISEER7.6430e-03-0.2135image
chr16:15408654-15412903:+HNSCGSVA_HALLMARK_MITOTIC_SPINDLEEER4.2534e-02-0.2432image
ENSG00000156968.8,MPV17LHNSCGSVA_HALLMARK_MITOTIC_SPINDLEEAG4.2534e-02-0.2432image
ENSG00000156968.8,MPV17LKICHGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG3.7184e-020.3116image
chr16:15408654-15412903:+KICHGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER3.7184e-020.3116image
chr16:15408654-15412903:+KIRCGSVA_HALLMARK_HEME_METABOLISMEER1.3446e-07-0.2945image
ENSG00000156968.8,MPV17LKIRCGSVA_HALLMARK_HEME_METABOLISMEAG1.3383e-07-0.2945image
ENSG00000156968.8,MPV17LKIRPGSVA_HALLMARK_PROTEIN_SECRETIONEAG6.1280e-03-0.1757image
chr16:15408654-15412903:+KIRPGSVA_HALLMARK_PROTEIN_SECRETIONEER6.1345e-03-0.1757image
chr16:15408654-15412903:+LGGGSVA_HALLMARK_MITOTIC_SPINDLEEER1.0503e-03-0.1561image
ENSG00000156968.8,MPV17LLGGGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.0503e-03-0.1561image
chr16:15408654-15412903:+LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEER1.4900e-07-0.2763image
ENSG00000156968.8,MPV17LLIHCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.4860e-07-0.2764image
ENSG00000156968.8,MPV17LLUADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.4649e-030.2287image
chr16:15408654-15412903:+LUADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.4649e-030.2287image
chr16:15408654-15412903:+LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.1355e-020.1681image
ENSG00000156968.8,MPV17LLUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.1355e-020.1681image
ENSG00000156968.8,MPV17LOVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.7589e-03-0.2368image
chr16:15408654-15412903:+OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.7562e-03-0.2369image
chr16:15408654-15412903:+PAADGSVA_HALLMARK_DNA_REPAIREER3.8050e-020.2028image
ENSG00000156968.8,MPV17LPAADGSVA_HALLMARK_DNA_REPAIREAG3.8050e-020.2028image
chr16:15408654-15412903:+PCPGGSVA_HALLMARK_MITOTIC_SPINDLEEER1.1810e-06-0.3798image
ENSG00000156968.8,MPV17LPCPGGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.1810e-06-0.3798image
ENSG00000156968.8,MPV17LPRADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.9982e-030.1527image
chr16:15408654-15412903:+PRADGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER2.9982e-030.1527image
ENSG00000156968.8,MPV17LREADGSVA_HALLMARK_MYC_TARGETS_V2EAG1.5270e-02-0.3380image
chr16:15408654-15412903:+READGSVA_HALLMARK_MYC_TARGETS_V2EER1.5270e-02-0.3380image
chr16:15408654-15412903:+SARCGSVA_HALLMARK_MITOTIC_SPINDLEEER6.6870e-03-0.2274image
ENSG00000156968.8,MPV17LSARCGSVA_HALLMARK_MITOTIC_SPINDLEEAG6.6870e-03-0.2274image
ENSG00000156968.8,MPV17LSKCMGSVA_HALLMARK_MYC_TARGETS_V1EAG3.9245e-020.2035image
chr16:15408654-15412903:+SKCMGSVA_HALLMARK_MYC_TARGETS_V1EER3.9245e-020.2035image
ENSG00000156968.8,MPV17LSTADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG8.0624e-04-0.2167image
chr16:15408654-15412903:+STADGSVA_HALLMARK_BILE_ACID_METABOLISMEER7.7025e-04-0.2175image
ENSG00000156968.8,MPV17LTGCTGSVA_HALLMARK_SPERMATOGENESISEAG9.3964e-04-0.2879image
chr16:15408654-15412903:+TGCTGSVA_HALLMARK_SPERMATOGENESISEER9.3964e-04-0.2879image
chr16:15408654-15412903:+THCAGSVA_HALLMARK_PROTEIN_SECRETIONEER5.2144e-08-0.2453image
ENSG00000156968.8,MPV17LTHCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG5.2144e-08-0.2453image
chr16:15408654-15412903:+THYMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.3523e-02-0.3973image
ENSG00000156968.8,MPV17LTHYMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.3523e-02-0.3973image
ENSG00000156968.8,MPV17LUCECGSVA_HALLMARK_COAGULATIONEAG3.6820e-030.4242image
chr16:15408654-15412903:+UCECGSVA_HALLMARK_COAGULATIONEER3.6820e-030.4242image
ENSG00000156968.8,MPV17LUVMGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.9082e-02-0.2972image
chr16:15408654-15412903:+UVMGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER2.9082e-02-0.2972image


Top

7. Enriched editing regions and drugs for MPV17L


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr16:15408654-15412903:+ACCLapatinibEER2.5509e-04-0.4520image
ENSG00000156968.8,MPV17LACCLapatinibEAG2.5509e-04-0.4520image
ENSG00000156968.8,MPV17LBLCACHIR.99021EAG4.5048e-02-0.1999image
chr16:15408654-15412903:+BLCACHIR.99021EER4.5048e-02-0.1999image
ENSG00000156968.8,MPV17LBRCACCT007093EAG4.4062e-170.2740image
chr16:15408654-15412903:+BRCACCT007093EER2.6123e-170.2759image
chr16:15408654-15412903:+CESCDasatinibEER1.0649e-06-0.4654image
ENSG00000156968.8,MPV17LCESCDasatinibEAG1.0644e-06-0.4654image
chr16:15408654-15412903:+CHOLCMKEER2.4201e-03-0.5791image
ENSG00000156968.8,MPV17LCHOLCMKEAG2.4201e-03-0.5791image
chr16:15408654-15412903:+COADGW843682XEER6.6342e-050.3272image
ENSG00000156968.8,MPV17LCOADGW843682XEAG4.7450e-050.3333image
ENSG00000156968.8,MPV17LESCAGSK269962AEAG1.1739e-03-0.3280image
chr16:15408654-15412903:+ESCAGSK269962AEER1.1739e-03-0.3280image
ENSG00000156968.8,MPV17LGBMCMKEAG7.7646e-03-0.2131image
chr16:15408654-15412903:+GBMCMKEER7.7646e-03-0.2131image
chr16:15408654-15412903:+HNSCA.770041EER3.7928e-03-0.3441image
ENSG00000156968.8,MPV17LHNSCA.770041EAG3.7928e-03-0.3441image
ENSG00000156968.8,MPV17LKICHA.770041EAG2.4690e-02-0.3346image
chr16:15408654-15412903:+KICHA.770041EER2.4690e-02-0.3346image
chr16:15408654-15412903:+KIRCCEP.701EER4.2479e-10-0.3456image
ENSG00000156968.8,MPV17LKIRCCEP.701EAG4.2473e-10-0.3456image
chr16:15408654-15412903:+KIRPFH535EER1.5084e-030.2029image
ENSG00000156968.8,MPV17LKIRPFH535EAG1.5143e-030.2028image
chr16:15408654-15412903:+LGGBX.795EER9.7850e-030.1233image
ENSG00000156968.8,MPV17LLGGBX.795EAG9.7850e-030.1233image
chr16:15408654-15412903:+LIHCDasatinibEER4.5242e-04-0.2019image
ENSG00000156968.8,MPV17LLIHCDasatinibEAG4.5159e-04-0.2020image
ENSG00000156968.8,MPV17LLUADDMOGEAG3.3895e-02-0.1716image
chr16:15408654-15412903:+LUADDMOGEER3.3895e-02-0.1716image
chr16:15408654-15412903:+LUSCBMS.536924EER3.6985e-03-0.1928image
ENSG00000156968.8,MPV17LLUSCBMS.536924EAG3.6985e-03-0.1928image
ENSG00000156968.8,MPV17LOVA.770041EAG2.4676e-04-0.2761image
chr16:15408654-15412903:+OVA.770041EER2.4560e-04-0.2762image
chr16:15408654-15412903:+PAADBAY.61.3606EER3.6398e-030.2896image
ENSG00000156968.8,MPV17LPAADBAY.61.3606EAG3.6398e-030.2896image
chr16:15408654-15412903:+PCPGBryostatin.1EER2.1456e-07-0.4033image
ENSG00000156968.8,MPV17LPCPGBryostatin.1EAG2.1456e-07-0.4033image
ENSG00000156968.8,MPV17LPRADBMS.708163EAG1.5495e-030.1627image
chr16:15408654-15412903:+PRADBMS.708163EER1.5495e-030.1627image
chr16:15408654-15412903:+SARCGNF.2EER3.8804e-03-0.2417image
ENSG00000156968.8,MPV17LSARCGNF.2EAG3.8804e-03-0.2417image
chr16:15408654-15412903:+SKCMBMS.509744EER6.1213e-03-0.2684image
ENSG00000156968.8,MPV17LSKCMBMS.509744EAG6.1213e-03-0.2684image
ENSG00000156968.8,MPV17LSTADCamptothecinEAG6.5774e-04-0.2202image
chr16:15408654-15412903:+STADCamptothecinEER6.7329e-04-0.2198image
ENSG00000156968.8,MPV17LTGCTAZD.0530EAG2.7897e-04-0.3148image
chr16:15408654-15412903:+TGCTAZD.0530EER2.7897e-04-0.3148image
chr16:15408654-15412903:+THCAGDC.0449EER1.4703e-10-0.2871image
ENSG00000156968.8,MPV17LTHCAGDC.0449EAG1.4703e-10-0.2871image
ENSG00000156968.8,MPV17LUCECJW.7.52.1EAG9.2647e-05-0.5495image
chr16:15408654-15412903:+UCECJW.7.52.1EER9.2647e-05-0.5495image
ENSG00000156968.8,MPV17LUCSCMKEAG2.1296e-03-0.5471image
chr16:15408654-15412903:+UCSCMKEER2.1296e-03-0.5471image
chr16:15408654-15412903:+UVMCamptothecinEER1.0931e-02-0.3437image
ENSG00000156968.8,MPV17LUVMCamptothecinEAG1.0931e-02-0.3437image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType